NEW YORK, NY / ACCESSWIRE / August 29, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Vitality Biopharma, Inc. (OTCQB: VBIO).

The report is available here: VBIO August 2016 Update Note.

We are updating our coverage of Stevia First Corp. to reflect the company’s shift in strategy and its July 2016 name change to Vitality Biopharma, Inc. (OTCQB: VBIO, “Vitality Biopharma”). The Vitality Biopharma brand reflects a pivot by management to focus its efforts on the development of cannabinoids for the treatment of serious neurological and inflammatory disorders. Initially, Vitality Biopharma has identified multiple sclerosis and inflammatory bowel disease as target markets.

These represent large market opportunities, with approximately 1.4mn Americans living with inflammatory bowel disease and more than 400,000 Americans suffering from MS. Concurrent with the company’s official name change to Vitality Biopharma, the company also completed a 10:1 reverse split and updated its ticker to OTCQB: VBIO. In our view, the market potential for the company’s new line of cannabinoid prodrugs represents a large and attractive opportunity if VBIO management is able to execute on its regulatory and commercialization plans over the next several years. We are updating our price target to $2.00 reflecting the new share count and strategic focus.

Additional highlights from the update note are as follows:

Stevia First becomes Vitality Biopharma, enters cannabinoid prodrugs market

In July 2016 Stevia First changed the name of its parent company to Vitality Biopharma, Inc. In a letter to investors, management explained the move by both acknowledging that its commercialization efforts for stevia had proven to be more difficult and take longer than originally expected, and also highlighting that it had identified a large new market in which it could leverage significant technologies developed in its pursuit of stevia: cannabinoid pharmaceutical prodrugs. Specifically, Vitality Biopharma discovered that stevia UGT enzymes could be used to enable the production of a new class of cannabinoid prodrugs. The market for legal marijuana / cannabis is growing; IMS Health estimate legal marijuana sales at $2.57 billion in 2014, while the synthetic cannabinoid market was pegged at $133mn.

Initially targeting MS, inflammatory bowel disease

Vitality Biopharma has already internally produced more than 20 novel cannabinoid glycosides, or cannabosides, using this process. These act as part of a class of medications known as “prodrugs,” which are essentially compounds administered in an inactive form but that become a pharmacologically active once they are metabolized. There are many advantages to Vitality Biopharma’s approach to the cannabinoid market using prodrugs, including better targeting, better dosing, a lower risk regulatory pathway, and the ability to leverage the clinical investigation history of the reference drug. Vitality Biopharma will initially be focused on developing prodrug therapeutics with multiple sclerosis and inflammatory bowel disease as target markets, and is expected to commence Phase 1 / Phase 2 trials in each of these areas in 2017E.

Updating price target to $2.00

We are updating our price target to reflect a reverse split undertaken by the company as well as new assumptions for the value of the cannabinoid and businesses. We see Vitality Biopharma as a company that offers both high risk and high growth potential as it targets the fast-growing emerging market for cannabinoid pharmaceutical prodrugs.

Please review important disclosures at www.seethruequity.com.

About Vitality Biopharma, Inc.

Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 444427

ORLANDO, FL / ACCESSWIRE / August 29, 2016 / MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the “Company”) specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its second quarter and six months 2016 results.

For the three months ended June 30, 2016, the Company reports $2.8 million of revenues, an increase of 32% compared to last year’s second quarter. Gross profit increased by 31% to $1.3 million primarily due to a higher sales percentage of higher margin Company manufactured equipment. Higher R&D expenses and professional fees resulted in an operating loss of $0.1 million.

For the six months ended June 30, 2016, revenue increased by 12% to $4.9 million, and gross profit increased by 16% to $2.2 million. Similar to the second quarter, higher R&D expenses and professional fees resulted in an operating loss of $0.5 million compared to $0.2 million loss for the six months ended June 30, 2015. The significant increase in interest expense to a total of $0.4 million was mainly due to non-cash charges for the issuance of warrants associated with a $0.65 million bridge loan. As a result, the net loss for the six months is $0.8 million.

Even though the Company’s Cash position decreased by $0.4 million to $0.1 million at December 31, 2015, the Company’s working capital is approximately $.7 million net of amounts due to employees. Management is pursuing ongoing initiatives to raise additional funds.

By hiring a highly experienced U.S. national sales manager and also hiring an industry professional as national marketing manager, we are moving towards our goal of significantly increasing United States sales, which currently represent approximately 5% of sales. The larger sales team is focused on building relationships and working closely with multi-market distribution channels concentrating on the Healthcare, Education, Medical Research and Pharmaceutical markets. These third party sales teams have just finished an intense training program on our core product line at the Orlando headquarters, and they have already made an impact reflected in new orders from both new and existing customers. In addition, MEDITE’s first attendance at a Hospital Group Purchasing (GPO) trade show, the “Premier Break Through” Exhibit in Washington DC, has exposed the Company to many new purchase manager contacts and interested potential customers from within this GPO network. In particular, large laboratories have shown a great deal of interest in our products after they became aware for the first time of MEDITE’s high quality and value products. According to Michael Ott, COO of MEDITE: “Once they test and use our equipment, we anticipate a significant percentage will order our products. With five exhibits scheduled in 2016 we will be able to reach many more of our core customers and end-users for hands on demonstrations.”

Positive results from our second quarter Chinese field study highlighted the innovative and newly developed fluorescence SureCyte stain, compared to the standard pap stain with improved efficiency of diagnosis. The evaluation of cervical specimens by Chinese pathologists confirmed 100 % identical results at a fraction of the cost and time used with the standard stains. The Chinese pathologists confirmed the new SureCyte stain is perfectly suitable for morphological staining. As a result, we expect to commence a September 2016 clinical trial using an automated fluorescence slide scanner for digital computer assisted screening addressing the need for high volume cancer screening. In addition, the SureCyte stain replaces the industry standard hazardous competitors’ Pap stains, is easier to use and apply, and reduces the staining process time from approximately one hour to just seconds. We believe the SureCyte stain based on existing regulations can be sold with either no or minimal USA or Chinese regulatory interactions.

More new and innovative MEDITE products will be presented at the major industry show for the United States organized by the National Society of Histotechnology from September 16 to 21 in Long Beach, California.

About MEDITE Cancer Diagnostics, Inc.

MEDITE Cancer Diagnostics Inc., is a Delaware registered company consisting of wholly-own MEDITE GmbH a Germany-based company with its subsidiaries. On April 3, 2014, MEDITE was acquired by former CytoCore, Inc. a biomolecular diagnostics company engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. By acquiring MEDITE the company changed from solely research operations to an operating company with a well-developed infrastructure, 80 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name and a wide range of products for anatomic pathology, histology and cytology laboratories.

Forward Looking Statement

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding future operating performance, events, trends and plans. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expects,” “intends,” “plans,” “projects,” “estimates,” “anticipates,” or “believes” or the negative thereof or any variation thereon or similar terminology or expressions. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause our actual results to differ from our expectations, include but are not limited to, MEDITE’s ability to maintain and grow its revenues. Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Such statements are not guarantees of future performance or events and we undertake no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances occurring after the date hereof.

For more information please visit: www.medite-group.com

Investor Contact:

Robert McCullough, Jr. CFO
407 996 9630

SOURCE: MEDITE Cancer Diagnostics, Inc.

ReleaseID: 444451

KUALA LUMPUR, MALAYSIA / ACCESSWIRE / August 29, 2016 / Vitaxel Group Limited (OTCQB: VXEL) (the “Company” or “Vitaxel”), announced the update on the License Agreement (the “Agreement”) the Company signed with Vitaxel Corp (Thailand) Ltd., a limited entity and incorporated in Thailand (“Licensee”).

The Agreement term is extended from three years with a three-year renewal to 10 years with 10-year renewal. The Company granted Licensee an exclusive, non-transferable, revocable license to use he Company’s trademarks, brands, logos or service marks to market and operate the Company’s business and commercialize the Company’s online shopping and service platforms including but not limited to the Company’s online shopping mall known as Vionmall, in Thailand during the period of 10 years with a possibility of renewal for another 10 years.

Ryan Leong, CEO of Vitaxel commented, “We are very excited to enter the Thailand market with the signing of a 10+10 – year License Agreement with Vitaxel Corp Ltd of Thailand. The Kingdom records a large populace of 11 million direct-sellers generating over USD2.698 Billion in sales last year. Our initial sales had been very encouraging and we anticipate Thailand will fast become a prime market for us.”

“This engagement is in addition to a similar License Agreement we recently signed with Vitaxel Private (Taiwan) Limited. The Company is also going to soft-launch our office in Taipei next month, the capital city of Taiwan which has a sophisticated market with over 2.3 Million Direct-Sellers contributing USD3.354 Billion in sales last year. we are eager to collaborate with experienced marketing teams there soon.”

“Vitaxel Group has also signed a Master Agreement with Bitspark Ltd, an innovative fintech firm based in Hong Kong, to offer its world’s first cash-in cash-out blockchain remittance service from Malaysia to neighboring Asian countries. The service currently hosts more than 80,000 cash-out points in the region. Vitaxel Group is working closely with Bitspark to establish the service in Malaysia and possible expansion into new corridors. The global remittance market is estimated at USD 581.6 billion in 2015 of which a major portion is contributed by countries in South and SE Asia. Meanwhile, Malaysia is currently home to approximately 1.993 Million foreign workers who regularly remit money back to their Asian home countries. There was an 23.2% increase in foreign worker remittances amounting to approximately USD8.69 Billion in 2015 compared to 2014. We believe that our endeavor will contribute positively towards the growth of Vitaxel Group,” Mr. Leong concluded.

About Vitaxel Group Limited

Vitaxel Group Limited is a market leader in MLM and e-commerce space, has over 5,200 distributors in more than 16 countries in Asia. With three significant operating subsidiaries, Vitaxel SDN BHD (Vitaxel) and Vitaxel Online Mall SDN BHD (Vionmall), and the Vitaxel Singapore PTE. Ltd. (“Vitaxel Singapore”), Vitaxel is primarily engaged in the direct selling industry utilizing a multi-level marketing model with an emphasis on travel, entertainment and lifestyle products and services; Vionmall is engaged in the development of online shopping platforms geared to Vitaxel and its members and third party providers of products and services.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic and other reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contacts:

Vitaxel Group Limited
Email: info@vitaxel.com
Phone: 03-2143 2889

SOURCE: Vitaxel Group Limited

ReleaseID: 444450

Canadian Cartoonist Dave Sim is Working on Reprinting the Popular Story of an Anthropomorphic Aardvark

LOS ANGELES, CA / ACCESSWIRE / August 29, 2016 / Canadian Cartoonist Dave Sim is pleased to announce that he is in the process of restoring Cerebus, the highly lauded graphic novel that centers on an anthropomorphic aardvark. One of the projects that he is currently working on is called CAN5 – Cerebus Archive Number Five.

To learn more about Cerebus, as well as read about the professional and talented award-winning team who is behind the innovative preservation and restoration of the popular graphic novel, please visit https://goo.gl/rNxVBk.

As a spokesperson for the project noted, Cerebus is a comic book series that ran from 1977 until 2004. The comic was created by Sim, an iconic cartoonist who was later joined by background artist and illustrator Gerhard.

Cerebus, the title character, took on a number of interesting and diverse roles during the series, including Prime Minister and Pope. In addition to the interesting story lines, fans of Cerebus enjoyed the eye-catching artwork.

“An ongoing effort is being made to restore and preserve Sim’s 6,000 page epic, Cerebus,” the spokesperson said.

“The Cerebus Archive project aims to ensure the highest quality future reprinting of the 16 Cerebus trade-paperbacks, allowing for the beloved comic to remain available to fans for generations and continue to inspire readers.”

In order to help pay for the huge restoration project, Sim recently launched a fundraiser on Kickstarter. He hopes to use crowdfunding to raise needed money to help get the restored copies into the hands of his established and appreciative readers, as well as introduce the fascinating tale of Cerebus to a new generation of fans.

To encourage people to contribute to his Kickstarter campaign, Sim is also offering the Cerebus Archive Number Five as a pledge item.

“This is a folio of the ten earliest Jaka’s Story pages in the Cerebus Archive with commentary by Dave Sim,” the spokesperson noted, adding that this is a limited edition, numbered and signed set of plates, digitally reproduced from Dave and Gerhard’s original art, exactly as he drew it, with all of the blue lines, pencil lines and aging discolouration, at 100 percent size.

About CAN 5 – Cerebus Archive Number Five:

Cerebus, the highly lauded graphic novel centering on an anthropomorphic aardvark, is in the process of being restored. Cerebus Archive Number Five, which is part of the restoration and preservation, is also available as a pledge item to people who contribute to the Cerebus Archive project. For more information, please visit https://goo.gl/rNxVBk.

Contact:

Jacob Mann
admin@rocketfactor.com
(949) 555-2861

SOURCE: CAN 5 – Cerebus Archive Number Five

ReleaseID: 444437

RADNOR, PA / ACCESSWIRE / August 29, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP alerts The GEO Group, Inc. (NYSE: GEO) (“GEO” or the “Company”) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Company’s securities between March 1, 2012 and August 17, 2016, inclusive (the “Class Period”).

Shareholders who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299-7706 or at info@ktmc.com.

GEO shareholders who purchased securities during the Class Period may seek to be designated by the Court as a lead plaintiff representative of the class. For additional information please visit https://www.ktmc.com/new-cases/geo-group#join.

GEO provides government-outsourced services, including the management of correctional and detention facilities in the United States and internationally.

The complaint alleges that GEO and certain of its executive officers made a series of false and misleading statements and/or failed to disclose to investors during the Class Period that: (i) GEO’s facilities lacked adequate safety and security standards and were less efficient at offering correctional services than the Federal Bureau of Prisons’ (“BOP”) facilities; (ii) GEO’s rehabilitative services for inmates were less effective than those provided by BOP; (iii) consequently, the U.S. Department of Justice (“DOJ”) was unlikely to renew and/or extend its contracts with GEO; and (iv) as a result of the foregoing, GEO’s public statements were materially false and misleading at all relevant times.

As detailed in the complaint, on August 18, 2016, Deputy Attorney General Sally Yates announced the DOJ’s decision to end its use of private prisons, including those operated by GEO, after officials concluded that GEO’s facilities are both less safe and less effective at providing correctional services than those run by the federal government.

Following this news, shares of the Company’s stock declined $12.78 per share, or nearly 40 percent, to close on August 18, 2016 at $19.51 per share, on unusually heavy trading volume.

GEO shareholders may, no
later than October 24, 2016, petition the Court to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. For additional information please visit https://www.ktmc.com/new-cases/geo-group#join.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, or for additional information about participating in this action, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
Darren J. Check, Esq.
D. Seamus Kaskela, Esq.
Adrienne O. Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 444332

BURLINGTON, ON / ACCESSWIRE / August 29, 2016 / GTA Mining and Resources Inc. (TSXV: GTA) (“GTA” or the “Company”) reports preliminary metallurgical testing from the Northshore Property. Results from two composites, one from core of the Afric Zone and one from core of the high-grade Audney vein system, returned peak gold recoveries of 96.3% and 99.5% respectively. The Company recently reported the results of 36 drill holes from those two areas (see press release dated 22-Aug-2016) as part of its on-going evaluation of the at/near surface potential of the Afric Zone.

Preliminary metallurgical test work was conducted on two composited drill core samples to determine potential gold recoveries. The preliminary metallurgical work was performed by Act Labs in Thunder Bay, and consisted of standard cyanide bottle roll testing with atomic absorption analysis for gold. Sample “A” weighed 43.9 kg and had an assayed head grade varying from 2.65 to 2.93 g/t gold. Sample “D”, from the high-grade Audney vein system, weighed 9.6 kg and had an assayed head grade varying from 11.6 to 10.9 g/t gold.

Jennifer Steyn, Metallurgy Manager, Act Labs stated, “These results indicate that the mineralization is free milling and excellent recoveries can be made using conventional cyanidation”. A full version of the “Gold Cyanidation Report” can be found on the company website at www.gtaresources.com.

Peak recovery was achieved after 24 hours for sample D at 99.5%. Sample A reached 94.8% recovery in 24 hours, peaking at 96.3% after 48 hours. Cyanide and lime consumption during the tests are considered by ACT Labs to be “fairly average”.

“We are very encouraged with these results as reported today,” commented Wayne Reid, President and CEO of GTA. “Although this is preliminary metallurgical work, these results indicate that the higher grade sections at the core of the Afric Zone should be relatively simple to process and have excellent gold recoveries.”

The Northshore Gold Property is located in Priske Township, near the town of Schreiber, Ontario, approximately 200 km east of Thunder Bay or 125 km west of Hemlo, Ontario. It is a joint venture with Balmoral Resources Ltd. (see press release dated Aug. 18, 2014). GTA is the operator and owns more than a 51% interest in the project. GTA is funding 100% of recent field work as Balmoral has opted not to participate in this phase of the program and will be diluted accordingly.

QA/QC – The planning, execution and monitoring of GTA’s exploration programs on the Northshore Project are under the supervision of Robert (Bob) Duess, P. Geo. (Ontario), VP Exploration of GTA. Mr. Duess is a qualified person as defined by National Instrument 43-101 and is also the Qualified Person for this release. Mr. Duess has supervised the work programs on the Northshore Property, and has also reviewed and approved this release.

Metallurgical work as summarized in this press release was performed by Act Labs in Thunder Bay, Ontario with ISO 17025 accreditation.

In other news, GTA announces the resignation of Robert Duess, Director and Vice President of Exploration. Mr. Duess was a founding member and leader of GTA Resources and Mining. He will stay on as an advisor where his knowledge and experience will continue to help guide the company. The resignation will be effective October 20, 2016 prior to GTA’s Annual General Meeting.

ABOUT GTA – GTA is a publicly traded mineral exploration company. It is led by an experienced and successful management team and is focused on exploring for gold and zinc in Canada. GTA is a tightly held company having 40,266,855 shares outstanding of which insiders control approximately 21% and its JV partner holding an additional 8%. The Company’s shares trade on the TSX Venture Exchange under the symbol “GTA.” The Company currently has two projects located in northern Ontario: the 51% owned Northshore Project, near Schreiber and the 100% owned Auden Project near Hearst. GTA also owns a 100% interest in the Burnt Pond Project in central Newfoundland, proximal to the past-producing Duck Pond Cu-Zn Mine.

On behalf of the board of directors

GTA Resources and Mining Inc.

“Wayne Reid”
President and CEO
709 699 1733

For more information, please visit the corporate website at www.gtaresources.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release contains forward-looking statements and forward-looking information (collectively, “forward looking statements”) within the meaning of applicable Canadian and United States securities laws. All statements, other than statements of historical fact, included herein, including statements regarding the anticipated content, commencement, duration and cost of exploration programs, anticipated exploration program results, the discovery and delineation of mineral deposits/resources/reserves, the timing of the receipt of assay results, and business and financing plans and trends, are forward-looking statements. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions or are those which, by their nature, refer to future events. Although the Company believes that such statements are reasonable, there can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future performance, and that actual results may differ materially from those in forward-looking statements. Important factors that could cause actual events and results to differ materially from the Company’s expectations include those related to weather, equipment and staff availability; performance of third parties; risks related to the exploration stage of the Company’s projects; market fluctuations in prices for securities of exploration stage companies and in commodity prices; and uncertainties about the availability of additional financing; risks related to the Company’s ability to identify one or more economic deposits on the properties, and variations in the nature, quality and quantity of any mineral deposits that may be located on the properties; risks related to the Company’s ability to obtain any necessary permits, consents or authorizations required for its activities on the properties; and risks related to the Company’s ability to produce minerals from the properties successfully or profitably. Trading in the securities of the Company should be considered highly speculative. All of the Company’s public disclosure filings may be accessed via www.sedar.com and readers are urged to review these materials, including the latest technical reports filed with respect to the Company’s mineral properties.

This press release is not, and is not to be construed in any way as, an offer to buy or sell securities in the United States.

SOURCE: GTA Mining and Resources Inc.

ReleaseID: 444448